We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

120 hedge funds and large institutions have $416M invested in Cymabay Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 42 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

268% more call options, than puts

Call options by funds: $3.5M | Put options by funds: $951K

99% more capital invested

Capital invested by funds: $209M → $416M (+$207M)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

5% more funds holding

Funds holding: 114 → 120 (+6)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

31% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 42

Holders
120
Holders Change
+6
Holders Change %
+5.26%
% of All Funds
2.42%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
29
Increased
29
Reduced
42
Closed
23
Calls
$3.5M
Puts
$951K
Net Calls
+$2.54M
Net Calls Change
+$2.16M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$27M
2
BC
Boxer Capital
California
+$10.7M
3
Invesco
Invesco
Georgia
+$9.53M
4
BBA
Baker Bros. Advisors
New York
+$9.25M
5
Millennium Management
Millennium Management
New York
+$4.48M

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$9.09M
2
ECM
Engine Capital Management
New York
-$6.16M
3
SCM
Sio Capital Management
New York
-$6.1M
4
FCMI
Foresite Capital Management IV
California
-$5.65M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$5.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$2.96M +$190K +35,500 +10%
Voloridge Investment Management
27
Voloridge Investment Management
Florida
$2.85M +$2.1M +392,912 New
EI
28
EAM Investors
California
$2.56M +$1.89M +354,337 New
KPWS
29
Kestra Private Wealth Services
Texas
$2.5M +$1.6M +300,000 New
EGI
30
EAM Global Investors
California
$2.06M +$1.52M +284,534 New
CCM
31
Copernicus Capital Management
California
$2.02M -$45.9K -8,584 -3%
FI
32
Fosun International
China
$1.91M – – –
N
33
Nuveen
North Carolina
$1.82M -$53.5K -9,998 -4%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.79M -$115K -21,525 -8%
Two Sigma Investments
35
Two Sigma Investments
New York
$1.77M -$339K -63,376 -21%
Jacobs Levy Equity Management
36
Jacobs Levy Equity Management
New Jersey
$1.61M -$420K -78,609 -26%
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.33M -$326K -60,936 -25%
HIM
38
Hillsdale Investment Management
Ontario, Canada
$1.18M -$283K -53,000 -25%
Renaissance Technologies
39
Renaissance Technologies
New York
$1.15M +$376K +70,400 +80%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$1.15M +$29.4K +5,500 +4%
A
41
Abingworth
United Kingdom
$947K – – –
Mackenzie Financial
42
Mackenzie Financial
Ontario, Canada
$877K +$648K +121,200 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$777K -$75.7K -14,165 -12%
AllianceBernstein
44
AllianceBernstein
Tennessee
$772K – – –
CAM
45
ClariVest Asset Management
California
$766K -$35.3K -6,600 -6%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$760K – – –
BCM
47
Bridgeway Capital Management
Texas
$711K -$2.14M -399,300 -80%
Goldman Sachs
48
Goldman Sachs
New York
$655K -$3.34M -624,397 -87%
TCM
49
Tekla Capital Management
Massachusetts
$638K – – –
TRCT
50
Tower Research Capital (TRC)
New York
$545K +$323K +60,354 +406%
1
2
3 4 5

CBAY Hedge Fund Activity: Q3 2020 in Review

120 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2020, worth a combined $416M — up 99% from $209M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CBAY positions and 23 closed out — a net gain of 6 holders — while 29 added to existing stakes and 42 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $27M. The largest seller was D.E. Shaw & Co, cutting an estimated $9.09M.

  • 120 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2020, up from 114 in Q2 2020.
  • Funds reported $416M of Cymabay Therapeutics stock for Q3 2020, up 99% quarter-over-quarter.
  • 29 funds opened new Cymabay Therapeutics positions in Q3 2020 and 23 closed out, a net change of +6 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2020 was Avoro Capital Advisors, an estimated $27M added.
  • The largest Cymabay Therapeutics seller in Q3 2020 was D.E. Shaw & Co, an estimated $9.09M sold.

Based on aggregated 13F filings for Q3 2020.